Jenburkt Pharmaceuticals Ltd vs Kopran Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Jenburkt Pharmaceuticals Ltd is ₹ 1044 as of 30 Apr 15:30 . The P/E Ratio of Jenburkt Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Kopran Ltd changed from 7.4 on March 2021 to 21.9 on March 2025 . This represents a CAGR of 24.23% over 5 years The Market Cap of Jenburkt Pharmaceuticals Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Kopran Ltd changed from ₹ 453.94 crore on March 2021 to ₹ 845.48 crore on March 2025 . This represents a CAGR of 13.25% over 5 years The revenue of Jenburkt Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Kopran Ltd for the Dec '25 is ₹ 194.35 crore as compare to the Sep '25 revenue of ₹ 117.93 crore. This represent the growth of 64.8% The ebitda of Jenburkt Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Kopran Ltd for the Dec '25 is ₹ 17.83 crore as compare to the Sep '25 ebitda of ₹ -5.25 crore. This represent the decline of -439% The net profit of Jenburkt Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Kopran Ltd changed from ₹ 11.1 crore to ₹ 9.34 crore over 7 quarters. This represents a CAGR of -9.39% The Dividend Payout of Jenburkt Pharmaceuticals Ltd changed from 28.37 % on March 2021 to 24.76 % on March 2025 . This represents a CAGR of -2.69% over 5 yearsThe Dividend Payout of Kopran Ltd changed from 55.28 % on March 2021 to 53.94 % on March 2025 . This represents a CAGR of -0.49% over 5 years .

About Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Limited, incorporated in 1985, was formed a joint venture to diversify into the healthcare and pharmaceutical industry, by Bhuta family.
The Company is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products. Presently, the Company manufactures and markets pharmaceutical formulations in India and internationally across 13 countries.
It has more than 1,000 stockists and their reach extends to 400,000+ pharmacies across the globe.
The organisation caters to government, semi-government institutions, missionary hospitals, public sector enterprises, etc. Apart from this. the Company operate manufacturing plant at Sihor-Gujarat, approved as per W.H.O (World Health Organisation) guidelines with current Good Manufacturing Practices (GMP) requirements.

About Kopran Ltd

Kopran Limited, incorporated on April 26, 1958, was promoted by the Somani group and is a group company of Parijat Enterprises.
Company operates in two distinct business verticals.
While pharmaceutical formulations production is managed by Kopran Limited, manufacturing of API is operated under Kopran Research Laboratories Limited (KRLL).
Company specialise in developing and manufacturing Penicillin and non-penicillin-based drugs.
Leveraging cutting-edge technology, it manufactures highquality finished dosage drugs that adhere to international requirements.

FAQs for the comparison of Jenburkt Pharmaceuticals Ltd and Kopran Ltd

Which company has a larger market capitalization, Jenburkt Pharmaceuticals Ltd or Kopran Ltd?

Market cap of Jenburkt Pharmaceuticals Ltd is 460 Cr while Market cap of Kopran Ltd is 795 Cr

What are the key factors driving the stock performance of Jenburkt Pharmaceuticals Ltd and Kopran Ltd?

The stock performance of Jenburkt Pharmaceuticals Ltd and Kopran Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Jenburkt Pharmaceuticals Ltd and Kopran Ltd?

As of May 3, 2026, the Jenburkt Pharmaceuticals Ltd stock price is INR ₹1044.25. On the other hand, Kopran Ltd stock price is INR ₹164.7.

How do dividend payouts of Jenburkt Pharmaceuticals Ltd and Kopran Ltd compare?

To compare the dividend payouts of Jenburkt Pharmaceuticals Ltd and Kopran Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.